drugset / Trial / NCT07404865
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease (UPSTREAM SjD)
Timeline
- Start
- 2026-02-26
- Primary completion
- 2028-12
- Completion
- 2029-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telitacicept | Protein / enzyme biologic | — | Subcutaneous |